OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research report issued on Friday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Up 1.6 %

Shares of OpGen stock opened at $1.25 on Friday. OpGen has a one year low of $0.53 and a one year high of $9.90. The stock’s fifty day moving average is $1.02 and its 200 day moving average is $1.56.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.